NovoCure Limited
NVCRHealthcareNASDAQMedical Devices
Scan Results
Daily timeframeNovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the. Valued at $1.92B, NVCR is a small-cap name in its sector. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax.
Market Cap
$1.92B
Beta
0.90
P/E (TTM)
—
P/E (Fwd)
-14.14
EPS (TTM)
$-1.53
EPS (Fwd)
$-1.17
ROE
-50.0%
ROA
-11.1%
Cash
$432.0M
Total Debt
$234.9M
Free CF
$5.1M
52W Change
-2.8%
Annual Financials
Cash vs Debt
With $432.0M in cash and $234.9M in debt, NVCR maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Annual free cash flow of $5.1M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at -50.0%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $535.0M (2021) to $655.4M (2025), reflecting a 22% increase over the period.
As with any equity investment, NVCR carries market risk, sector-specific risk, and company-specific risk that investors should evaluate in the context of their own portfolios. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing NVCR.